Logo
x

Search

Subscribe Now

All Posts by Date

Dr. Volker Knappertz, EVP R&D, Aurinia Shares Insights on LUPKYNIS MAA from EMA

Dr. Volker Knappertz, EVP R&D, Aurinia Shares Insights on LUPKYNIS MAA from EMA

  • December 7, 2022
Ascletis Receives the US FDA’s IND Approval of ASC11 for the Treatment of COVID-19

Ascletis Receives the US FDA’s IND Approval of ASC11 for the Treatment of COVID-19

  • December 7, 2022
Eli Lilly Presents P-III (monarchE) Trial Results of Verzenio (abemaciclib) for Early Breast Cancer at SABCS 2022

Eli Lilly Presents P-III (monarchE) Trial Results of Verzenio (abemaciclib) for Early Breast Cancer at SABCS 2022

  • December 7, 2022
Ultromics’ EchoGo Heart Failure as a Breakthrough Device Receives the US FDA’s Clearance for the Detection of Heart Failure with Preserved Ejection Fraction

Ultromics’ EchoGo Heart Failure as a Breakthrough Device Receives the US FDA’s Clearance for the Detection of Heart Failure with P...

  • December 7, 2022
AbbVie Entered into an Exclusive Worldwide Collaboration and Option to License Agreement with HotSpot Therapeutics for IRF5 Program

AbbVie Entered into an Exclusive Worldwide Collaboration and Option to License Agreement with HotSpot Therapeutics for IRF5 Progra...

  • December 7, 2022
Akeso Out Licenses its Ivonescimab to Summit for ~$5B

Akeso Out Licenses its Ivonescimab to Summit for ~$5B

  • December 7, 2022
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.